OncoSec Medical

OncoSec Medical

Employees:
40
Market Cap:
$32.95 million
Revenue:
$0.0
5 Year Trend:
0.0%
Net Income:
$-23.24 million
NASDAQ:
ONCS

OncoSec Medical

Employees:
40
Market Cap:
$32.95 million
Revenue:
$0.0
5 Year Trend:
0.0%
Net Income:
$-23.24 million
NASDAQ:
ONCS
  • Oct 30 at 9:38 PM
    Breast Cancer affects many lives. Talk to your doctor about screening, family history and prevention today! #breastcancerawarenessmonth
  • Oct 23 at 5:53 PM
    Reminder: Be sure to tune in this Wednesday as we discuss our Q4 + 2017 Fiscal Year End updates! Click here for more details: http://bit.ly/2ztOlAt
  • Oct 19 at 4:50 PM
    We are pleased to announce updated data from our single-agent monotherapy trial (Phase 2 OMS-I100) and combination study (Phase 2 OMS-I102) in melanoma with ImmunoPulse IL-12, the latter in combination with pembrolizumab. In our combination study, we demonstrated a 50% (11/22) best overall response rate (BORR) at 24 weeks and a 38.1% [8/21] durable complete response, as measured by RECIST v1.1. "We are encouraged by the data from these analyses, which continue to show that ImmunoPulse IL-12 can prime the immune system to help improve patient response to anti-PD-1," said Dr. Alain Algazi, Lead Trial Investigator, Associate Professor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. "The complete response rates observed in the Phase 2 study assessing the combination of ImmunoPulse IL-12 and pembrolizumab in the predicted anti-PD-1 non-responder patient population provide compelling early evidence that the combination could lead to a clinically meaningful impact on patient outcomes." Click here for more details: http://bit.ly/2yyMFFU
  • Oct 11 at 9:35 PM
    It has been an exciting week for OncoSec! Today we announced our acceptance of a late breaking abstract at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 in November! We will be presenting updated clinical data from our phase 2 IST trail assessing the combination of our investigational therapy, ImmunoPulse IL-12, and the approved anti-PD-1 therapy pembrolizumab, in patients with unresectable metastatic melanoma. Additionally, we will present preclinical data from our novel multi-gene expression platform termed PIIM (Polycistronic Interleukin-12 Immune Modulator) as a poster presentation at the same meeting. To learn more about our planned presentations at #SITC2017, please visit: http://bit.ly/2g3HJQY

Oct 30, 9:38 PM

Breast Cancer affects many lives. Talk to your doctor about screening, family history and prevention today! #breastcancerawarenessmonth

Oct 23, 5:53 PM

Reminder: Be sure to tune in this Wednesday as we discuss our Q4 + 2017 Fiscal Year End updates! Click here for more details: http://bit.ly/2ztOlAt

Oct 19, 4:50 PM

We are pleased to announce updated data from our single-agent monotherapy trial (Phase 2 OMS-I100) and combination study (Phase 2 OMS-I102) in melanoma with ImmunoPulse IL-12, the latter in combination with pembrolizumab. In our combination study, we demonstrated a 50% (11/22) best overall response rate (BORR) at 24 weeks and a 38.1% [8/21] durable complete response, as measured by RECIST v1.1. "We are encouraged by the data from these analyses, which continue to show that ImmunoPulse IL-12 can prime the immune system to help improve patient response to anti-PD-1," said Dr. Alain Algazi, Lead Trial Investigator, Associate Professor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. "The complete response rates observed in the Phase 2 study assessing the combination of ImmunoPulse IL-12 and pembrolizumab in the predicted anti-PD-1 non-responder patient population provide compelling early evidence that the combination could lead to a clinically meaningful impact on patient outcomes." Click here for more details: http://bit.ly/2yyMFFU

Oct 11, 9:35 PM

It has been an exciting week for OncoSec! Today we announced our acceptance of a late breaking abstract at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 in November! We will be presenting updated clinical data from our phase 2 IST trail assessing the combination of our investigational therapy, ImmunoPulse IL-12, and the approved anti-PD-1 therapy pembrolizumab, in patients with unresectable metastatic melanoma. Additionally, we will present preclinical data from our novel multi-gene expression platform termed PIIM (Polycistronic Interleukin-12 Immune Modulator) as a poster presentation at the same meeting. To learn more about our planned presentations at #SITC2017, please visit: http://bit.ly/2g3HJQY